MEDIA

NEWS

MetaSight Diagnostics Raises $8M in Over-Subscribed Series A Funding Round

November 2024

MetaSight Diagnostics Emerges from Stealth and Announces Partnership with Maccabi's KSM Research and Innovation Center to Conduct Extensive Metabolomics Research

July 2023

Forbes article featuring MetaSight: “Apparently Getting Smarter Makes Us Healthier: AI And Data Analysis Revolutionize Healthcare”

July 2023

PUBLICATIONS

MetaSight to present at the American Association for the Study of Liver Diseases: The Liver Meeting 2024. Metabolic Dysfunction-Associated Steatohepatitis (MASH)-fibrosis score: A blood test enabling patient monitoring of liver fibrosis

November 2024

American Association for the Study of Liver Diseases: The Liver Meeting 2023. A NOVEL SERUM DIAGNOSTIC SIGNATURE FOR LIVER FIBROSIS AND “AT RISK” MASH VALIDATED IN A POPULATIONSCALE SCREENING

November 2023

MetaSight to present at the American Society For Mass Spectrometry (ASMS) annual conference: “Untargeted LC-MS Metabolomics Screening of 500,000 Serum Samples Identifies Novel Biomarkers for Cancer, Cardiovascular, & Liver Diseases”

June 2023

MetaSight to present at the European Association for the Study of the Liver (EASL) annual conference: “A mass-spectrometry serum test for identifying liver fibrosis and at-risk NASH enabling cost-effective population screening”

June 2023

MEDIA CONTACT

For media inquiries please contact MetaSight at office@metasightdx.com